AAVrh10.alphaPA

AAVrh10.alphaPA is an experimental gene therapy using the adeno-associated virus serotype rh10 (AAVrh10) as a viral vector to deliver a therapeutic transgene. AAVrh10 is distinguished by its enhanced ability to transduce neurons and glial cells in the central and peripheral nervous system and efficiently cross the blood-brain barrier, making it of interest for treating neurological diseases and certain genetic disorders. The suffix “alphaPA” likely designates a proprietary or experimental therapeutic payload not explicitly described in the literature provided. AAVrh10-based therapies have been investigated preclinically for disorders such as lysosomal storage diseases and leukodystrophies, but "AAVrh10.alphaPA" itself does not correspond to any approved drug or major clinical-stage product as of September 2025[2][4].